Michael S. Ip

9.3k total citations · 2 hit papers
159 papers, 5.4k citations indexed

About

Michael S. Ip is a scholar working on Ophthalmology, Radiology, Nuclear Medicine and Imaging and Molecular Biology. According to data from OpenAlex, Michael S. Ip has authored 159 papers receiving a total of 5.4k indexed citations (citations by other indexed papers that have themselves been cited), including 144 papers in Ophthalmology, 112 papers in Radiology, Nuclear Medicine and Imaging and 19 papers in Molecular Biology. Recurrent topics in Michael S. Ip's work include Retinal Diseases and Treatments (124 papers), Retinal Imaging and Analysis (92 papers) and Retinal and Optic Conditions (77 papers). Michael S. Ip is often cited by papers focused on Retinal Diseases and Treatments (124 papers), Retinal Imaging and Analysis (92 papers) and Retinal and Optic Conditions (77 papers). Michael S. Ip collaborates with scholars based in United States, United Kingdom and Switzerland. Michael S. Ip's co-authors include Ingrid U. Scott, Barbara A. Blodi, Paul VanVeldhuisen, Neal L. Oden, Andrew Hendrick, Jason S. Ehrlich, Amitha Domalpally, Clement K. Chan, Michael J. Tolentino and Srinivas R. Sadda and has published in prestigious journals such as Physical Review Letters, JAMA and SHILAP Revista de lepidopterología.

In The Last Decade

Michael S. Ip

148 papers receiving 5.2k citations

Hit Papers

A Randomized Trial Comparing the Efficacy and Safety of I... 2008 2026 2014 2020 2009 2008 100 200 300 400 500
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. A Randomized Trial Comparing the Efficacy and Safety of Intravitreal Triamcinolone With Observation to Treat Vision Loss Associated With Macular Edema Secondary to Central Retinal Vein Occlusion
    2009 535 citations Michael S. Ip, Ingrid U. Scott et al. profile →
  2. A Randomized Trial Comparing Intravitreal Triamcinolone Acetonide and Focal/Grid Photocoagulation for Diabetic Macular Edema
    2008 413 citations Michael S. Ip Ophthalmology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Michael S. Ip United States 37 5.0k 3.7k 778 349 191 159 5.4k
Alexander J. Brucker United States 33 4.4k 0.9× 2.8k 0.8× 844 1.1× 291 0.8× 184 1.0× 119 4.9k
José Garcia-Arumı́ Spain 39 3.9k 0.8× 2.8k 0.8× 881 1.1× 545 1.6× 260 1.4× 171 4.6k
Enrico Borrelli Italy 38 4.6k 0.9× 3.7k 1.0× 721 0.9× 208 0.6× 189 1.0× 269 5.0k
Rosa Dolz‐Marco Spain 28 2.8k 0.6× 1.8k 0.5× 547 0.7× 192 0.6× 156 0.8× 155 3.1k
Andrew A. Moshfeghi United States 30 2.9k 0.6× 1.9k 0.5× 567 0.7× 174 0.5× 165 0.9× 111 3.5k
Christina J. Flaxel United States 38 5.7k 1.1× 4.3k 1.2× 564 0.7× 196 0.6× 358 1.9× 145 6.3k
Ramin Tadayoni France 49 7.7k 1.5× 6.2k 1.7× 1.2k 1.5× 835 2.4× 270 1.4× 238 8.4k
Horst Helbig Germany 32 2.0k 0.4× 1.4k 0.4× 836 1.1× 392 1.1× 154 0.8× 227 3.1k
Gary W. Abrams United States 42 4.3k 0.9× 3.0k 0.8× 845 1.1× 1.0k 2.9× 161 0.8× 117 5.2k
Andrew N. Antoszyk United States 27 3.1k 0.6× 2.5k 0.7× 414 0.5× 87 0.2× 139 0.7× 53 3.5k

Countries citing papers authored by Michael S. Ip

Since Specialization
Citations

This map shows the geographic impact of Michael S. Ip's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michael S. Ip with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michael S. Ip more than expected).

Fields of papers citing papers by Michael S. Ip

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Michael S. Ip. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michael S. Ip. The network helps show where Michael S. Ip may publish in the future.

Co-authorship network of co-authors of Michael S. Ip

This figure shows the co-authorship network connecting the top 25 collaborators of Michael S. Ip. A scholar is included among the top collaborators of Michael S. Ip based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Michael S. Ip. Michael S. Ip is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Lakhani, Moiz, Marko M. Popovic, Nikhil S. Patil, et al.. (2025). Comparative Analysis of Ocular Adverse Events between Aflibercept 8 mg and Faricimab. Ophthalmology Retina.
2.
Ip, Michael S., et al.. (2025). Treatment Patterns and Long-term Outcomes with Anti–VEGF Therapy for Retinal Vein Occlusion. Ophthalmology Retina. 9(12). 1187–1196.
3.
Wang, Xiaolin, Sujin Hoshi, Giulia Corradetti, et al.. (2025). Photoreceptor Function and Structure in Retinal Areas With Intraretinal Hyperreflective Foci in Age-Related Macular Degeneration. Investigative Ophthalmology & Visual Science. 66(2). 27–27.
4.
5.
Chang, Dolly S., Natalia F. Callaway, Karl G. Csaky, et al.. (2023). Macular Sensitivity Endpoints in Geographic Atrophy. SHILAP Revista de lepidopterología. 4(1). 100351–100351. 22 indexed citations
6.
Strauß, Rupert W., Alexander Ho, Anamika Jha, et al.. (2023). Progression of Stargardt Disease as Determined by Fundus Autofluorescence Over a 24-Month Period (ProgStar Report No. 17). American Journal of Ophthalmology. 250. 157–170. 9 indexed citations
7.
Kaiser, Peter K., Paul Karpecki, Carl D. Regillo, et al.. (2023). Geographic Atrophy Management Consensus (GA-MAC): a Delphi panel study on identification, diagnosis and treatment. BMJ Open Ophthalmology. 8(1). e001395–e001395. 6 indexed citations
8.
VanderBeek, Brian L., Yinxi Yu, Neal L. Oden, et al.. (2023). Visit Adherence and Visual Acuity in Study of COmparative Treatments for REtinal Vein Occlusion 2 (SCORE2). Ophthalmic Epidemiology. 31(1). 78–83.
9.
Wykoff, Charles C., Muneeswar Gupta Nittala, Hannah J. Yu, et al.. (2022). Final Outcomes from the Randomized RECOVERY Trial of Aflibercept for Retinal Nonperfusion in Proliferative Diabetic Retinopathy. Ophthalmology Retina. 6(7). 557–566. 8 indexed citations
10.
Kong, Xiangrong, Millena Bittencourt, Rupert W. Strauß, et al.. (2021). Longitudinal Changes in Scotopic and Mesopic Macular Function as Assessed with Microperimetry in Patients With Stargardt Disease: SMART Study Report No. 2. American Journal of Ophthalmology. 236. 32–44. 6 indexed citations
11.
Velaga, Swetha Bindu, Adrian Au, Muneeswar Gupta Nittala, et al.. (2021). Pentosan Polysulfate Maculopathy: Prevalence, Spectrum of Disease, and Choroidal Imaging Analysis Based on Prospective Screening. American Journal of Ophthalmology. 227. 125–138. 36 indexed citations
12.
Diesfeld, Kate, et al.. (2018). New Zealand’s Health Practitioners Disciplinary Tribunal: An Analysis of Decisions 2004-2014.. PubMed. 24(1). 239–51. 6 indexed citations
13.
Fan, Wenying, Kang Wang, Khalil Ghasemi Falavarjani, et al.. (2017). Distribution of Nonperfusion Area on Ultra-widefield Fluorescein Angiography in Eyes With Diabetic Macular Edema: DAVE Study. American Journal of Ophthalmology. 180. 110–116. 75 indexed citations
14.
Scott, Ingrid U., et al.. (2016). Study of COmparative Treatments for REtinal Vein Occlusion 2 (SCORE2): Baseline Characteristics of the SCORE2 Population. Investigative Ophthalmology & Visual Science. 57(12). 5154–5154. 1 indexed citations
15.
Ehrlich, Jason S., Amitha Domalpally, Linda Yau, J. Jill Hopkins, & Michael S. Ip. (2013). Effects of Intravitreal Ranibizumab on Diabetic Retinopathy Severity: 36 Month Data from the RISE and RIDE Phase III Trials. Investigative Ophthalmology & Visual Science. 54(15). 4028–4028. 1 indexed citations
16.
Blodi, B. A., et al.. (2008). Reading Center Evaluation of Baseline Retinal Images in the Standard Care vs. Corticosteroid for Retinal Vein Occlusion (SCORE) Study. Investigative Ophthalmology & Visual Science. 49(13). 2136–2136. 2 indexed citations
17.
Alster, Yair, Neil M. Bressler, Susan B. Bressler, et al.. (2005). Preferential Hyperacuity Perimeter (PreView PHP) for Detecting Choroidal Neovascularization Study. Ophthalmology. 112(10). 1758–1765. 62 indexed citations
18.
Pearson, P. Andrew, Carl W. Baker, Dean Eliott, et al.. (2003). Fluocinolone Acetonide Intravitreal Implant in Patients with Diabetic Macular Edema: 12 Month Results. Investigative Ophthalmology & Visual Science. 44(13). 4288–4288. 4 indexed citations
19.
Hovland, Peter, et al.. (2003). Photodynamic Therapy of Subfoveal and Juxtafoveal Choroidal Neovascularization Secondary to Nongranulomatous Uveitis. Investigative Ophthalmology & Visual Science. 44(13). 4876–4876. 1 indexed citations
20.
Ip, Michael S., et al.. (2003). Treatment of Central Retinal Vein Occlusion with Intravitreal Triamcinolone Acetonide. Investigative Ophthalmology & Visual Science. 44(13). 3217–3217. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Alexander J. Brucker Breakdown of academic impact, for papers by José Garcia-Arumı́ Breakdown of academic impact, for papers by Enrico Borrelli Breakdown of academic impact, for papers by Rosa Dolz‐Marco Breakdown of academic impact, for papers by Andrew A. Moshfeghi Breakdown of academic impact, for papers by Christina J. Flaxel Breakdown of academic impact, for papers by Ramin Tadayoni Breakdown of academic impact, for papers by Horst Helbig Breakdown of academic impact, for papers by Gary W. Abrams Breakdown of academic impact, for papers by Andrew N. Antoszyk
Rankless by CCL
2026